Moment Of Truth For Belantamab Mafodotin, Trikafta And Turalio At EMA
A number of drug companies are set to learn the fate of their marketing authorization applications in the EU this week.
You may also be interested in...
GlaxoSmithKline's potential multiple myeloma treatment is one of several new products that could get an EU marketing thumbs up from the European Medicines Agency this week.
EU approval is likely for the eight medicines that got the thumbs up this week from the European Medicines Agency's drug evaluation committee, the CHMP. The panel held fire on one product it had been considering and also issued its first rejection of 2020.
Gilead Sciences’ remdesivir could get the nod from the European Medicines Agency this week as a treatment for COVID-19, paving the way for swift EU approval.